Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2418-2425

  Johansen, Kirsten L ^a   Finkelstein, Fredric O ^b   Revicki, Dennis A ^c   Evans, Christopher ^d   Wan, Shaowei ^e   Gitlin, Matthew ^e   Agodoa, Irene L ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b YALE UNIVERSITY   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d MAPI VALUES   (United States)

^e AMGEN INC   (United States)

Author keywords

Anemia; Dialysis; ESA; Fatigue; Hemoglobin

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; DRUG SUBSTITUTION; FATIGUE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE QUESTIONNAIRE; KIDNEY FAILURE; MAINTENANCE THERAPY; MEASUREMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NOTTINGHAM HEALTH PROFILE; PRIORITY JOURNAL; PROFILE OF MOOD STATES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SHORT FORM 36; SYSTEMATIC REVIEW;

ADULT; FATIGUE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS;

EID: 84861840837     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr697     Document Type: Review

References (39)

1. Lasch KF, Evans CJ, Schatell D. A qualitative analysis of patientreported symptoms of anemia. Nephrol Nurs J 2009; 36: 621-622
2. Weisbord SD, Fried LF, Mor MK et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2007; 2: 960-967
3. Koyama H, Fukuda S, Shoji T et al. Fatigue is a predictor for cardiovascular outcomes in patients undergoing hemodialysis. Clin J Am Soc Nephrol 2010; 5: 659-666
4. Keown PA, Churchill DN, Poulin-Costello M et al. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 2010; 14: 168-173
5. Smith RE Jr. The clinical and economic burden of anemia. Am J Manag Care 2010; 16 (Suppl Issues): S59-S66
6. National Anemia Action Council. http://www.anemia.org/resources/ education-kit/quick-facts.php (29 November 2011, date last accessed)
7. National Kidney Foundation. http://www.kidney.org/news/wkd/SixStepsKH.cfm (29 November 2011, date last accessed)
8. Renal Support Network. http://www.rsnhope.org/WeKANAdvocacy/AnemiaFacts. pdf (29 November 2011, date last accessed)
9. U.S. Department of Health and Human Services. National Heart Lung and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/ida/signs. html (29 November 2011, date last accessed)
10. Johansen KL, Finkelstein FO, Revicki DA et al. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 2010; 55: 535-548
11. Gandra SR, Finkelstein FO, Bennett AV et al. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis 2010; 55: 519-534
12. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300: 573-578
13. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
14. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
15. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
16. Singh AK, Szczech L, Tang KL et al. Correction of anemia with Epoetin Alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
17. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Control Clin Trials 1991; 12: 168S-179S
18. Ware JE, Snow K, Kosinski M et al. SF-36 Health Survey Manual and Interpretation Guide. Lincoln, RI: QualityMetric Inc, 1993.
19. Hunt SM, McEwen J. The development of a subjective health indicator. Sociol Health Illn 1980; 2: 231-246
20. McNair DM, Lorr M, Droppelman LF. Manual for the Profile of Mood States. Toronto, Canada: Multi-Health Systems, Inc, 1992.
21. FACIT. http://www.facit.org/FACITOrg (29 November 2011, date last accessed)
22. Meyer KB, Espindle DM, DeGiacomo JM et al. Monitoring dialysis patients' health status. Am J Kidney Dis 1994; 24: 267-279
23. Hunt SM, McKenna SP, McEwen J et al. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med A 1981; 15: 221-229
24. Hunt S. Nottingham health profile. In: Wenger NK, Mattson ME, Furberg CD et al (eds). Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York, NY: Le Jacq Publishing, 1984, 165-169
25. Dworkin RH, Turk DC, Farrar JT et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 9-19
26. Yellen SB, Cella DF, Webster K et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74
27. Auer J, Simon G, Stevens J et al. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia. Perit Dial Int 1992; 12: 40-42
28. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990; 263: 825-830
29. Wolcott DL, Marsh JT, La Rue A et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; 14: 478-485
30. Muirhead N, Churchill DN, Goldstein M et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 1992; 12: 303-310
31. Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant 1992; 7: 811-816
32. Levin N, Lazarus J, Nissenson A. Maximizing patient benefits with epoetin alfa therapy: the National Cooperative rHu Erythropoietin study in patients with chronic renal failure-an interim report. Am J Kidney Dis 1993; 22: 3-12
33. Beusterien KM, Nissenson AR, Port FK et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
34. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
35. Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361
36. Fukuhara S, Akizawa T, Morita S et al. Quality of life improvements in dialysis patients receiving darbepoetin alfa. Ther Apher Dial 2008; 12: 72-77
37. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189
38. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 2009; 4: 726-733
39. Clement FM, Klarenbach S, Tonelli M et al. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1104-1112